Changes in Brain Volumes Are Relevant during Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: Lessons from a Case Report

Int J Mol Sci. 2022 Nov 7;23(21):13642. doi: 10.3390/ijms232113642.

Abstract

This is a case report concerning a Natalizumab-associated Progressive Multifocal Leukoencephalopathy (PML) with cerebellar localization and wakefulness disturbances. Awakening and clinical improvement dramatically occurred as soon as the immune reconstitution inflammatory syndrome (IRIS) took place, being it mild in nature and colocalizing with the PML lesion. In these ideal experimental conditions, we applied brain magnetic resonance imaging post-analysis in order to know changes in brain volumes underlying the pathological process over the infection period. White matter volume increased with a decrease in grey matter during IRIS. Conversely, we found a constant increase in cerebrospinal fluid volume throughout the duration of PML, suggesting a widespread abiotrophic effect, far from the lesion. Furthermore, brain parenchymal fraction significantly decreased as expected while the total brain volume remained stable at all times. Neurodegeneration is the main contributor to the steady disability in Natalizumab-associated PML. This process is thought to be widespread and inflammatory in nature as well as sustained by IRIS and humoral factors derived from the PML lesion.

Keywords: JC virus; MRI post-processing; brain segmentation; multiple sclerosis; progressive multifocal leukoencephalopathy.

Publication types

  • Case Reports

MeSH terms

  • Brain / diagnostic imaging
  • Brain / pathology
  • Humans
  • Immune Reconstitution Inflammatory Syndrome* / complications
  • Immune Reconstitution Inflammatory Syndrome* / etiology
  • Leukoencephalopathy, Progressive Multifocal* / diagnostic imaging
  • Leukoencephalopathy, Progressive Multifocal* / etiology
  • Leukoencephalopathy, Progressive Multifocal* / pathology
  • Magnetic Resonance Imaging
  • Multiple Sclerosis* / pathology
  • Natalizumab / adverse effects

Substances

  • Natalizumab

Grants and funding

This research received no external funding.